CDKN2A and melanoma: The low rate of monthly SSE observed in our sample is similar to that reported for individuals from CDKN2A mutation-positive families in the United States (17% Aspinwall et al, 2008), as well as melanoma survivors (15% Manne and Lessin, 2006) and individuals with multiple dysplastic nevi (10–20% Oliveria et al, 2004).